Ind-Swift Laboratories Limited has informed the Exchange regarding Board meeting held on August 11, 2025.

Ind-Swift Laboratories' board approved audited financial results for Q4 and the full year ended March 31, 2025 (standalone and consolidated, on a post-merger basis) at its meeting on August 11, 2025. The amalgamation of Ind-Swift Limited with the company was sanctioned by the NCLT Chandigarh Bench on July 17, 2025 and became effective on August 8, 2025, with an appointed date of March 31, 2024; pooling of interest method was applied, recognizing a capital reserve of Rs. 46,588.29 lakhs. The board also allotted 14,20,000 1% Redeemable Preference Shares of Rs. 100 each to preference shareholders of Ind-Swift Limited on the same terms, with redemptions to happen in tranches. Standalone FY25 net profit was Rs. 25,608.53 lakhs versus Rs. 53,617.88 lakhs in FY24 (comparatives restated due to pooling of interest), while consolidated FY25 net profit was Rs. 25,047.66 lakhs versus Rs. 53,875.07 lakhs in FY24. Reported profits were supported by a large exceptional gain of Rs. 39,099.82 lakhs. Statutory auditor Rattan Kaur & Associates gave an unmodified opinion with multiple Emphasis of Matter notes covering warrant conversion into equity, the amalgamation, completion of fixed deposit repayment under the 2013 scheme, and sale of plant and machinery at Unit-III Baddi along with other land and building disposals. Net cash from operating activities was negative at Rs. -3,915.39 lakhs for the year.